针对 COVID-19 的异源初免-加强接种：安全且可靠吗？
Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
机构信息
Department of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, India.
Independent Researcher, 07, Type IV Quarter, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, India.
出版信息
Hum Vaccin Immunother. 2021 Dec 2;17(12):5135-5138. doi: 10.1080/21645515.2021.2007015. Epub 2021 Dec 13.
Abstract
Throughout the globe, many nations are struggling to cope with the consecutive waves of the COVID-19. Several vaccines have been employed to overcome this ongoing pandemic and are available as single and double-dose inoculations; however, homologous vaccine efficacy is being reconsidered due to the rapidly emerging SARS-CoV-2 variants. Many studies have been conducted on the heterologous prime-boost vaccine regimens and have shown good efficacy results against COVID-19. This article aims to highlight the safety and reliability of heterologous prime-boost vaccination against COVID-19. We have also made some recommendations towards using these combinations of vaccines for the global mitigation of the subsequent waves of COVID-19.
摘要
在全球范围内，许多国家正在努力应对 COVID-19 的连续波。已经使用了几种疫苗来克服这一持续的大流行，并可作为单剂和双剂接种；然而，由于 SARS-CoV-2 变体的迅速出现，同源疫苗的效力正在重新考虑。已经对异源初免-加强疫苗方案进行了许多研究，并显示出对 COVID-19 的良好疗效结果。本文旨在强调针对 COVID-19 的异源初免-加强疫苗接种的安全性和可靠性。我们还就使用这些疫苗组合为全球减轻 COVID-19 的后续浪潮提出了一些建议。
相似文献
1
Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?针对 COVID-19 的异源初免-加强接种：安全且可靠吗？
Hum Vaccin Immunother. 2021 Dec 2;17(12):5135-5138. doi: 10.1080/21645515.2021.2007015. Epub 2021 Dec 13.
2
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.异源初免-加强接种灭活 COVID-19 疫苗和 ChAdOx1 nCoV-19（AZD1222）疫苗的免疫原性和反应原性：一项准实验研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4.
3
Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.腺病毒载体二价疫苗在小鼠模型中对野生型 SARS-CoV-2 和奥密克戎变异株的免疫原性。
Vaccine. 2024 Feb 27;42(6):1292-1299. doi: 10.1016/j.vaccine.2024.01.073. Epub 2024 Jan 30.
4
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.科里纳平（COReNAPCIN）作为一种 SARS-CoV-2 mRNA 疫苗，在健康伊朗成年人中作为第四种异源加强针的安全性和免疫原性：一项双盲、随机、安慰剂对照、为期 6 个月随访的 1 期临床试验。
Int Immunopharmacol. 2024 Jun 15;134:112192. doi: 10.1016/j.intimp.2024.112192. Epub 2024 May 17.
5
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.异源加强免疫用腺病毒 5 型载体和基于蛋白亚单位的 COVID-19 疫苗（Convidecia/ZF2001）的安全性和免疫原性：一项随机、观察者设盲、安慰剂对照试验。
PLoS Med. 2022 May 26;19(5):e1003953. doi: 10.1371/journal.pmed.1003953. eCollection 2022 May.
6
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.COVID-19 疫苗异源初免-加强免疫的反应原性和免疫原性。
Biomed Pharmacother. 2022 Mar;147:112650. doi: 10.1016/j.biopha.2022.112650. Epub 2022 Jan 19.
7
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.BBIBP-CorV 和 ZF2001 异源加强免疫对 18 岁及以上健康成年人的 SARS-CoV-2 的安全性、免疫原性和免疫持久性。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):1079-1090. doi: 10.1080/14760584.2023.2274491. Epub 2023 Nov 8.
8
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性：一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
9
Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.同源与异源加强 COVID-19 疫苗接种在自体造血干细胞移植受者中的效果比较：一项盲法随机对照试验。
Front Immunol. 2023 Aug 1;14:1237916. doi: 10.3389/fimmu.2023.1237916. eCollection 2023.
10
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.CoronaVac 和 ChAdox1 nCov-19（AZD1222）疫苗异源初免-加强免疫后的免疫原性和反应原性。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24.
引用本文的文献
1
Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants.异源初免-加强免疫接种可驱动基质激活和针对新冠病毒变异株的适应性免疫。
Front Immunol. 2025 May 28;16:1597417. doi: 10.3389/fimmu.2025.1597417. eCollection 2025.
2
Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.SARS-CoV-2异源和同源加强免疫接种策略后严重不良事件的死亡率：一项回顾性队列研究。
PLoS One. 2025 May 23;20(5):e0323736. doi: 10.1371/journal.pone.0323736. eCollection 2025.
3
Impact of COVID-19 Pandemic on Routine Childhood Immunization Programs in Indonesia: Taking Rural and Urban Area into Account.新冠疫情对印度尼西亚儿童常规免疫规划的影响：兼顾农村和城市地区
Patient Prefer Adherence. 2024 Mar 13;18:667-675. doi: 10.2147/PPA.S448901. eCollection 2024.
4
Analysis on the Selection of Herbs in TCM COVID-19 Treatment Protocols Between Malaysia and China.马来西亚与中国中医新冠肺炎治疗方案中用药选择分析
Int J Gen Med. 2023 Aug 21;16:3655-3663. doi: 10.2147/IJGM.S426168. eCollection 2023.
5
Complete Genomic Characterisation and Mutation Patterns of Iraqi SARS-CoV-2 Isolates.伊拉克新冠病毒分离株的全基因组特征及突变模式
Diagnostics (Basel). 2022 Dec 21;13(1):8. doi: 10.3390/diagnostics13010008.
6
Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis.揭示 COVID-19 信息免疫学期刊传递的信息：文献计量学和可视化分析。
Front Immunol. 2022 Oct 31;13:1035151. doi: 10.3389/fimmu.2022.1035151. eCollection 2022.
7
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.德尔塔变异株（B.1.617.2）：SARS-CoV-2 的突变、影响、挑战及可能的解决方案。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2068883. doi: 10.1080/21645515.2022.2068883. Epub 2022 May 4.
8
Strategies and safety considerations of booster vaccination in COVID-19.COVID-19 加强针接种的策略和安全性考虑。
Bosn J Basic Med Sci. 2022 Jun 1;22(3):366-373. doi: 10.17305/bjbms.2021.7082.
本文引用的文献
1
India's COVID-19 vaccination drive: key challenges and resolutions.印度的新冠疫苗接种行动：关键挑战与解决方案
Lancet Infect Dis. 2021 Nov;21(11):1483-1484. doi: 10.1016/S1473-3099(21)00567-3. Epub 2021 Sep 13.
2
Fake COVID-19 vaccines: scams hampering the vaccination drive in India and possibly other countries.假 COVID-19 疫苗：骗局阻碍了印度乃至其他国家的疫苗接种工作。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4117-4118. doi: 10.1080/21645515.2021.1960770. Epub 2021 Aug 6.
3
Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.采用ChAdOx1 nCoV-19和BNT162b2进行异源初免-加强免疫接种。
Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.
4
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.异源ChAdOx1 nCoV-19疫苗和mRNA-1273疫苗接种
N Engl J Med. 2021 Sep 9;385(11):1049-1051. doi: 10.1056/NEJMc2110716. Epub 2021 Jul 14.
5
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.BNT162b2 加强剂在 ChAdOx1-S 初免参与者中的免疫原性和反应原性（CombiVacS）：一项多中心、开放标签、随机、对照、2 期临床试验。
Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25.
6
Second wave of COVID-19 in India: Dissection of the causes and lessons learnt.印度第二波新冠疫情：原因剖析与经验教训
Travel Med Infect Dis. 2021 Sep-Oct;43:102126. doi: 10.1016/j.tmaid.2021.102126. Epub 2021 Jun 16.
7
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.异源初免-加强型新型冠状病毒肺炎疫苗接种：初始反应原性数据
Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.
8
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的最新综述及大流行时期有效疫苗接种计划的重要性
Vaccines (Basel). 2021 Apr 27;9(5):433. doi: 10.3390/vaccines9050433.
9
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.美国 2021 年 4 月：在报告接种强生（Johnson & Johnson）新冠疫苗的人群中出现血栓性血小板减少综合征后，免疫实践咨询委员会更新了强生疫苗的使用建议。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.
10
India's role in COVID-19 vaccine diplomacy.印度在新冠疫苗外交中的作用。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab064.
Zotero 插件